What is Notable Labs?
Notable Labs operates at the intersection of biotechnology and data science, specializing in the development of predictive platforms that identify effective drug combinations for blood cancer patients. Unlike traditional pharmaceutical models that prioritize broad-spectrum patient populations, Notable Labs utilizes a high-resolution approach to isolate specific patient groups with unmet clinical requirements. By accurately forecasting the success rates of various therapeutic combinations, the company effectively reduces the trial-and-error cycle inherent in oncology treatment. This market position allows the firm to serve as a critical partner in the drug development lifecycle, transforming how clinicians and researchers approach personalized medicine in complex hematological malignancies.
How much funding has Notable Labs raised?
Notable Labs has raised a total of $57.4M across 6 funding rounds:
Angel/Seed
$6M
Other Financing Round
$50K
Series A
$10M
Series B
$40M
Debt
$350K
Debt
$1M
Angel/Seed (2015): $6M with participation from Accelerate Brain Cancer Cure, Eric Kwan, First Round Capital, Y Combinator, UpHonest Capital, Refactor Capital, and 11.2 Capital
Other Financing Round (2016): $50K led by Undisclosed
Series A (2017): $10M supported by Builders VC
Series B (2019): $40M featuring B Capital Group and Lifeforce Capital Gp I
Debt (2020): $350K backed by PPP
Debt (2021): $1M with participation from PPP
Key Investors in Notable Labs
B Capital Group
B Capital is a global venture capital firm that empowers entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors.
Y Combinator
Established in 2005, Y Combinator is a premier startup accelerator that provides seed funding and strategic guidance to high-growth technology businesses.
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions that reshape legacy systems.
What's next for Notable Labs?
With the support of its latest capital injection, Notable Labs is positioned to accelerate its clinical validation efforts and deepen its integration within the healthcare ecosystem. The strategic focus moving forward involves scaling its predictive engine to accommodate larger datasets and broader therapeutic applications. By leveraging its established relationships with top-tier venture partners, the company is well-equipped to navigate the complexities of regulatory approval and commercial expansion. The next phase of growth will likely prioritize the optimization of its proprietary technology to further reduce the time-to-market for life-saving drug combinations, ultimately aiming to set a new standard for efficacy in the treatment of blood cancers.
See full Notable Labs company page
